ArticleBMC nephrology2026
Dual therapeutic interventions to optimize vancomycin exposure and reduce nephrotoxicity: a cohort study from a single center.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVancomycin-associated Acute Kidney Injury (AKI) is a significant global concern, increasing healthcare costs, morbidity, and mortality. This Quality Improvement Project (QIP) aimed to reduce supratherapeutic vancomycin concentrations and AKI by lowering the trough target and implementing AUC (Area Under the Curve)-based dosing.
methodsThis was a single-center cohort study. Adult patients receiving intravenous vancomycin for at least 72 h were prospectively recruited from January to June 2022. Vancomycin trough target was revised from 15 to 20 mg/L to 10-20 mg/L, and a hybrid dosing strategy incorporating AUC-based dosing for eligible patients was piloted in five wards. A historical cohort from June to November 2021, managed with higher trough target of 15-20 mg/L, was investigated for comparison. The primary outcome was the rate of supratherapeutic vancomycin trough concentrations (> 20 mg/L). Secondary outcomes included AKI incidence, total vancomycin dose over the initial 72 h, in-hospital mortality, and operational metrics related to therapeutic drug monitoring.
resultsA total of 80 patients in the historical cohort and 57 in the QIP cohort were analysed. The rate of supratherapeutic vancomycin trough concentrations was lower in the QIP cohort compared with the historical cohort (11% vs. 20%, p < 0.01). AKI rate was lower in the QIP cohort, although not statistically significant (12% vs. 18%). In-hospital mortality was numerically lower in the QIP cohort (3.5% vs. 7.5%). The total vancomycin dose administered during the initial 72 h was significantly lower in the QIP cohort (83 [56-100] vs. 104 [76-119] mg/kg, p < 0.01). Vancomycin concentrations were monitored less frequently, while dose adjustments were similar between cohorts.
conclusionLowering the vancomycin trough target and adopting AUC dosing in selected patients reduced supratherapeutic vancomycin concentrations, and showed potential to lower nephrotoxicity, without requiring increased monitoring or dose adjustments. However, the small number of patients receiving AUC-guided dosing limits interpretation of its specific contribution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.